TABLE 3.
Serogroup C-specific IgG GMCs and 95% CIs before and 1, 2, 12, and 24 months following administration of Menitorix at 12 to 14 months of age, by priming MCC vaccine
| Time from administration of Menitorix (mo) | Parameter | Result obtained with the following priming meningococcal serogroup C conjugate vaccine: |
|||
|---|---|---|---|---|---|
| All combined | Meningitec | Menjugate | NeisVac-C | ||
| Preboosting | No. of subjects | 206 | 70 | 66 | 65 |
| GMC (95% CI) | 0.54 (0.48-0.62) | 0.52 (0.42-0.64) | 0.59 (0.47-0.73) | 0.53 (0.42-0.68) | |
| 1 | No. of subjects | 250 | 80 | 91 | 76 |
| GMC (95% CI) | 7.11 (6.35-7.95) | 6.73 (5.47-8.28) | 5.98 (5.04-7.09) | 9.39 (7.63-11.55) | |
| 2 | No. of subjects | 124 | 36 | 44 | 43 |
| GMC (95% CI) | 5.64 (4.78-6.66) | 5.00 (3.67-6.81) | 4.53 (3.44-5.96) | 8.02 (6.09-10.57) | |
| 12 | No. of subjects | 217 | 63 | 83 | 66 |
| GMC (95% CI) | 0.73 (0.63-0.84) | 0.65 (0.53-0.8) | 0.67 (0.52-0.86) | 0.90 (0.69-1.17) | |
| 24 | No. of subjects | 125 | 35 | 45 | 42 |
| GMC (95% CI) | 0.41 (0.34-0.48) | 0.43 (0.32-0.59) | 0.39 (0.30-0.51) | 0.41 (0.30-0.56) | |